PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC.

This corrects the article DOI: 10.1038/bjc.2017.85.

Immunotherapy has substantially improved the clinical outcome of several tumours, including cancers poorly responsive to chemotherapy (Robert ; Reck ). PD-L1 assessment in tumour tissue (i.e., NSCLC) allows to identify a patient population with higher likelihood of response with respect to chemotherapy (Reck ). However, changes in the activity of signal transduction patways (i.e., MAPK) (Jiang ) may affect PD-L1 levels, thus impairing its predictive value if assessed on a single-tissue biopsy. For these reasons, the interest of the scientific community is turning towards other potential biomarkers, such as mutational load and microsatellite instability (Rizvi ; Dudley ). Exosomes are microvesicles actively released from cancer cells; they have a size range of 40–150 nm and a lipid bilayer membrane and they carry proteins, RNA and DNA of cells from which they are originated (Kalluri, 2016). Their involvement in immune signalling, reprogramming of surrounding cells, as well as their ability to influence tumour microenvironment in favour of immune escape, therapy resistance, tumour growth and metastasis have been demonstrated (Kalluri, 2016).

For these reasons, the present study was aimed at evaluating PD-L1 mRNA expression in plasma-derived exosomes to monitor response to the anti-PD-1 agents nivolumab and pembrolizumab in melanoma and NSCLC.

Patients and methods

Patients

Patients affected by locally advanced or metastatic melanoma or NSCLC given nivolumab (240 mg i.v. every 2 weeks) or pembrolizumab (200 mg i.v. every 3 weeks) as per approved schedule were enroled. The experimental part of the study consisted of two blood drawings from each patient for the measurement of exosomal mRNA levels of PD-L1 at time 0 (baseline) and at the time of radiological assessment of disease status, i.e., after 2 months of treatment. Complete or partial responses (CR, PR), disease stabilisation (SD) and disease progression (PD) were defined following RECIST (v. 1.1) criteria.

Measurement of exosomal PD-L1

A blood sample of 6 ml was collected in EDTA tubes and centrifuged for 10 min at 1900 g within 2 hours. The isolation of exosomes from plasma and extraction of RNA was previously described (Del Re ) and performed using the exoRNeasy kit (Qiagen, Valencia, CA). The analysis of PD-L1 mRNA was performed by the QX100 ddPCR (Bio-Rad, Hercules, CA, USA) using the One-Step RT-ddPCR kit. The PrimePCR ddPCR Expression Probe Assay for CD274 (human) was used to assess PD-L1 expression and the human ß-actin ddPCR assay was used as internal control. Fluorescence signal quantification was performed by the droplet reader and the QuantaSoft software (Bio-Rad). The ratio of positive vs negative droplets was used to determine the number of mRNA copies per ml of the target molecule in the input reaction. Droplets with a fluorescence intensity threshold higher than 4000 were considered positive. Each plasma sample was extracted once and triplicate ddPCR analyses were performed per sample. The values reported below (copies per ml) represent the mean of the triplicate.

Statistical analysis

Inferential statistics was used to assess the significance of differences between paired samples (PD-L1 levels at time 0 vs 2 months; paired t-test) and unpaired groups (time 0 PR+CR vs SD+PD; unpaired t-test); the significance level was set at 5%. The GraphPad software (GraphPad Software, La Jolla, CA, USA online version) was used for statistical calculations.

Results

Eighteen patients with melanoma were enroled (Table 1); there were 2 CR, 8 PR, 2 SD and 6 PD. The number of mRNA copies per ml of PD-L1 in plasma-derived exosomes decreased in patients with CR/PR (mean 793.5 vs 231, time 0 vs 2 months, respectively), while it increased in patients with PD (mean 143.3 vs 326.7, time 0 vs 2 months, respectively). Two patients died, one due to PD (mRNA PD-L1 copies per ml increased from 90 to 360), and the other because of acute myocardial infarction, while on CR (PD-L1 mRNA decreased from 2000 to 1000 copies per ml). Table 2 reports a detailed description of PD-L1 changes.

Table 1

Clinical characteristics of patients

	Melanoma (n=18)	NSCLC (n=8)
Age
Median (range)	71 (45−87)	64 (52−77)
Gender
Male/female	12/6	5/3
ECOG PS
0/1−2	10/8	5/3
Tumour type
Squamous/adenocarcinoma		1/7
BRAF mutation
Yes/no	5/13
EGFR mutation
Yes/no		1/7
ALK translocation
Yes/no		0/8
First line immunotherapy	11/18	0/8

Abbreviations: ALK=anaplastic lymphoma kinase; BRAF=v-RAF murine sarcoma viral oncogene homolog B1; ECOG PS=Eastern Cooperative Oncology Group performance status; EGFR=epidermal growth factor receptor; NSCLC=non-small cell lung cancer.

Table 2

PD-L1 copies per ml in plasma-derived exosomes vs tumour response in patients treated with pembrolizumab or nivolumab for melanoma or NSCLC

Patient	Tumour type	Treatment	PD-L1 time 0 (copies per ml)	PD-L1 2 months (copies per ml)	Response
1	Melanoma	Nivolumab	500	240	CR
2a	Melanoma	Pembrolizumab	2000	1000	CR
3	Melanoma	Pembrolizumab	140	70	PR
4	Melanoma	Pembrolizumab	2500	0	PR
5	Melanoma	Pembrolizumab	180	220	PR
6	Melanoma	Pembrolizumab	1045	520	PR
7	Melanoma	Pembrolizumab	215	80	PR
8	Melanoma	Pembrolizumab	600	80	PR
9	Melanoma	Pembrolizumab	405	0	PR
10	Melanoma	Pembrolizumab	350	100	PR
11	NSCLC	Nivolumab	1700	400	PR
12	NSCLC	Nivolumab	330	200	PR
Mean±s.e.m.			830.4±231.3	242.5±82.5	P=0.016
13	Melanoma	Pembrolizumab	190	160	SD
14	Melanoma	Pembrolizumab	95	260	SD
15	NSCLC	Nivolumab	380	280	SD
16	NSCLC	Nivolumab	530	290	SD
Mean±s.e.m.			298.8±97.2	247.5±29.8	P=0.586
17b	Melanoma	Pembrolizumab	90	360	PD
20	Melanoma	Pembrolizumab	90	200	PD
21	Melanoma	Pembrolizumab	0	140	PD
22	Melanoma	Pembrolizumab	70	500	PD
18	Melanoma	Nivolumab	115	210	PD
19	Melanoma	Nivolumab	495	550	PD
23	NSCLC	Nivolumab	270	700	PD
24	NSCLC	Nivolumab	0	140	PD
25	NSCLC	Nivolumab	260	360	PD
26b	NSCLC	Nivolumab	650	1000	PD
Mean±s.e.m.			204.0±68.8	416.0±87.8	P=0.001

Abbreviations: CR=complete response; NSCLC=non-small cell lung cancer; PD=progression of disease; PR=partial response; SD=stable disease.

Patients were grouped on the basis of tumour response and mean±s.e.m. values of PD-L1 copies per ml are reported; P-values were calculated by paired t-test.

Death due to acute myocardial infarction.

Death due to PD.

Patients 4 and 9 reported a PR during treatment with pembrolizumab; perhaps unexpectedly, PD-L1 was undetectable in plasma at tumour re-assessment. However, exosomal ß-actin mRNA was detectable in these two patients (8.1 and 9.0 × 106 copies per ml, respectively), thus excluding a false negative result.

Eight patients with NSCLC were enroled in the study (Table 1); there were 2 PR, 2 SD and 4 PD. The mRNA copies per ml of PD-L1 were correlated with tumour response, with a clear increase in patients with PD (mean, 295 vs 550 copies per ml, time 0 vs 2 months, respectively) and decrease in patients who achieved a PR (mean, 1015 vs 300 copies per ml, time 0 vs 2 months, respectively). A modest variation was seen in patients with SD (mean 455 vs 285, time 0 vs 2 months, respectively) (Table 2). Figure 1 reports the data of 2 representative patients with NSCLC showing a PR and a PD; PD-L1 plasma levels varied in accordance with disease response or progression.

Figure 1

Effect of treatment with anti-PD-1 antibodies on exosomal PD-L1 expression and clinical response in NSCLC and melanoma. (A) Mean values of PD-L1 (copies per ml) evaluated in baseline (time 0, dark grey) and at tumour re-assessment after 2 months of treatment (light grey) in patients grouped according to tumour response (CR+PR, SD and PD); P-values are reported on top of the columns. ddPCR plots (B and C) showing PD-L1 exosomal mRNA variations during the follow up of 2 non-small cell lung cancer patients. The blue dots circled in blue represent PD-L1, whereas the green dots represent ß-actin. (B) PD-L1 expression at the time of patient entry into the study (1700 copies per ml) and reduction after 2 months (400 copies per ml); the patient showed a partial response. (C) detection of PD-L1 expression at baseline (270 copies per ml) and increase after 2 months (700 copies per ml); the subject had disease progression. CR=complete response; PD=progression of disease; PR=partial response; SD=stable disease.

In the overall population, the difference between PD-L1 mRNA copies per ml was significant both in patients with CR+PR (830.4±231.3 at time 0 vs 242.5±82.5 after 2 months, P=0.016) and with PD (204.0±68.8 vs 416.0±87.8, time 0 vs 2 months thereafter, P=0.001), but not, as expected, in patients with SD (298.8±97.2 at time 0 vs 247.5±29.8 after 2 months, P=0.586; Table 2). At time 0, subjects with CR and PR showed a significantly higher number of copies per ml of PD-L1 mRNA compared to subjects with SD and PD (830.4±231.3 vs 231.1±55.7, P=0.012; Table 2).

Discussion

This study first demonstrates exosomal PD-L1 expression changes during treatment with anti-PD-1 antibodies. Furthermore, the results show that PD-L1 levels in plasma-derived exosomes significantly decreased in patients responding to treatment and increased in subjects with disease progression, while, as expected, no significant changes were observed in patients with SD.

The issue of variability of PD-L1 expression in relation to its predictive role has been addressed in tissue biopsies collected in the same patients at different time-points (Cho ). The predictive role of PD-L1 expression in tumour tissue is still a matter of debate, since cancers with low expression of PD-L1 may respond to nivolumab and survival is longer than patients treated with chemotherapy (Borghaei ). Moreover, it is not known which effect other therapies, including chemotherapy and radiotherapy, may have on PD-L1 expression. Thus, its assessment in primary tumour at the time of diagnosis may not inform on changes which will occur during clonal evolution and selective pressure of treatments. Studies on circulating biomarkers are increasing in number because they can provide important information on dynamic response to treatment. Although they are not aimed at selecting patients for the administration of anti-PD-1/PD-L1 treatments, they have the potential to provide relevant information on clinical outcome. The assessment of PD-L1 expression in circulating tumour cells has been evaluated in bladder cancer and NSCLC for its potential capability to guide the selection of patients to be treated with anti-PD-1 or PD-L1 antibodies (Anantharaman ; Nicolazzo ). Other studies evaluating tumour mutational burden or microsatellite instability may also be suitable to personalise treatment, although they follow a different strategy and PD-L1 expression is not specifically addressed (Rizvi ; Dudley ).

The strategy of using exosomes in this study was suggested by their ability to preserve intact mRNA. Exosomes have an intriguing role in cancer signalling and immunity; they are involved in cell-to-cell communication, they reflect changes induced by treatment and, most importantly, they are involved in immune escape (Liu ). The ability of exosomes to communicate inhibitory signals to effector cells, including NK, macrophages, dendritic cells and T cells, may explain why the decline of PD-L1 in responding patients is associated with tumour response and possibly a restoration of cellular immunity. To confirm this hypothesis, larger cohorts of patients will be required, as well as a comparison of PD-L1 expression in paired tissue and plasma-derived exosomes.

In conclusion, the present work demonstrates in a limited population that dynamic measurement of PD-L1 expression in plasma-derived exosomes is feasible and may provide useful information on the response to treatment with anti-PD-1 antibodies.